Phase III EUROPA Clinical Trial: Impact on Radiation Oncology in Costa Rica.

The phase III EUROPA clinical trial is an international study that seeks to offer new treatment options for women over 70 years of age with breast cancer. Its objective is to compare the effectiveness of external radiotherapy with endocrine therapy as single treatments, with the hope of finding the best alternative for this population.

This study is especially relevant because it not only focuses on the effectiveness of the treatment, but also on the quality of life of patients. Through detailed follow-up, researchers seek to better understand how these treatments affect long-term health and well-being.

Although the first results are promising, it is still early to make definitive decisions about its implementation in Costa Rica. A longer follow-up time is required to accurately assess the impact of omitting hormone therapy in this group of patients. However, what is encouraging is that Costa Rica has the infrastructure and resources necessary in radiation oncology to apply innovative strategies such as this in the future.

This type of research represents an important step in the fight against breast cancer, offering new possibilities for each patient to receive the most appropriate treatment according to their individual needs and conditions.